{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:19:22Z","timestamp":1773350362092,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In the present network meta-analysis (NMA), we aimed to compare the effectiveness of daily and weekly treatment with glucagon-like peptide-1 receptor agonists for patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We used Stata 17.0 for the NMA. Eligible Randomized controlled trials (RCTs) were searched in PubMed, Cochrane, and Embase databases until December 2022. Two researchers independently screened the available studies. The Cochrane Risk of Bias tool was used to assess the risk of bias in the included studies. We used GRADEprofiler (version3.6) to analyze the evidence certainty. Primary outcomes such as liver fat content (LFC), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels, as well as secondary outcomes such as \u03b3-glutamyltransferase (\u03b3GGT) and body weight, were evaluated. Then, each intervention was ranked by the surface under the cumulative ranking curve (SUCRA). As a supplement, we drew forest plots of subgroup using RevMan (version 5.4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen RCTs involving 1666 participants were included in the present study. The NMA results showed that exenatide (bid) was the best treatment for improving LFC compared with other agents, liraglutide, dulaglutide, semaglutide (qw) and placebo), and the SUCRA values were 66.8%. Among five interventions (except exenatide (bid) and semaglutide (qw)) evaluated for AST outcome, and six interventions (except exenatide (bid)) evaluated for ALT outcome, semaglutide (qd) was the most effective drug (SUCRA (AST) = 100%, SUCRA (ALT) = 95.6%). The result of LFC in daily group was MD = -3.66, 95% CI [-5.56, -1.76] and in weekly GLP-1RAs group, it was MD = -3.51, 95% CI [-4, -3.02]. As to AST and ALT, the results in daily group versus weekly group were AST: MD = -7.45, 95% CI [-14.57, -0.32] versus MD= -0.58, 95% CI [-3.18, 2.01] and ALT: MD = -11.12, 95% CI [-24.18, 1.95] versus MD = -5.62, 95% CI [-15.25, 4]. The quality of evidence was assessed as moderate or low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The daily GLP-1RAs may be more effective in primary outcomes. And the daily semaglutide may be the most effective treatment for NAFLD and T2DM among the six interventions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1170881","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:59:22Z","timestamp":1685941162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Xia","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaixin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B2","article-title":"Treatment of non-alcoholic fatty liver disease: can we already face the epidemic","volume":"76","author":"Verbeek","year":"2013","journal-title":"Acta Gastroenterol Belg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza","year":"2021","journal-title":"Front Biosci (Landmark Ed)."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabetes Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14319","article-title":"Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(22)00440-8","article-title":"Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with nonalcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"77","author":"Loomba","year":"2022","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study [published correction appears in diabetes care. 2022 Dec 1;45(12):3112]","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2317-z","article-title":"Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial","volume":"54","author":"Samson","year":"2011","journal-title":"Diabetologia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1007\/s12072-020-10030-4","article-title":"Effect of liraglutide therapy on hepatic steatosis and liver stiffness in patients with nonalcoholic fatty liver disease","volume":"14","author":"Shahinul","year":"2020","journal-title":"Hepatol Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B28","first-page":"98","article-title":"Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss","volume":"26","author":"Luyckx","year":"2000","journal-title":"Diabetes Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00426.2010","article-title":"Obesity, diabetes mellitus, and liver fibrosis","volume":"300","author":"Chiang","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.609135","article-title":"Sodium-glucose Co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","article-title":"A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal","year":"2021","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.793203","article-title":"Efficacy of off-label therapy for non-alcoholic fatty liver disease in improving non-invasive and invasive biomarkers: a systematic review and network meta-analysis of randomized controlled trials","volume":"9","author":"Luo","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-2565","article-title":"Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects","volume":"29","author":"Larson-Meyer","year":"2006","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"108904","DOI":"10.1016\/j.diabres.2021.108904","article-title":"Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis","volume":"177","author":"Xia","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-020-01148-8","article-title":"Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis","volume":"19","author":"Chang","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"Van Can","year":"2014","journal-title":"Int J Obes (Lond)."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1170881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:59:25Z","timestamp":1685941165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1170881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":44,"alternative-id":["10.3389\/fendo.2023.1170881"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1170881","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"article-number":"1170881"}}